Royalty Pharma Plc (RPRX)

48.72 -0.10 (-0.22%) USD  |  NASDAQ  |  Apr 15, 16:00
48.72 0.00 (0.00%) After-Hours: 20:00
More

Royalty Pharma Research and Development Expense (Annual) : 452.00M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for RPRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Zymeworks, Inc. 137.00M
Johnson & Johnson 14.83B
Biogen, Inc. 1.481B
Revolution Medicines, Inc. 978.68M
Corcept Therapeutics, Inc. 254.91M